Drug intelligence / Profile preview

adebelizumab

Development stage: Phase 2
Lead developer: Shanghai Shengdi Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Adebelizumab is an immune checkpoint inhibitor that targets programmed death-ligand 1 (PD-L1). It is currently under investigation for the treatment of various cancers, including resectable locally advanced gastric/gastroesophageal junction cancer, extensive-stage small cell lung cancer, and advanced recurrent/metastatic endometrial cancer. The drug is being studied in combination with chemotherapy and/or radiotherapy in perioperative settings or as first-line and second-line treatments.

Other names: adebrelimabAdebelimab

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on adebelizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adebelizumab.

Explore the full profile